Literature DB >> 27593737

Preparation and evaluation of HPMC-based pirfenidone solution in vivo.

Mei Yang1, Yang-Fan Yang1, Ming Lei2, Cheng-Tian Ye1, Chun-Shun Zhao2, Jian-Gang Xu1, Kai-Li Wu1, Min-Bin Yu1.   

Abstract

CONTEXT: Pirfenidone (PFD) has exhibited therapeutic potential in the treatment of cell proliferative disorders. The previously developed 0.5% water-based PFD eye drops by our team exhibited antiscarring effectiveness and ocular safety but with a limit of short half-life and poor bioavailability.
OBJECTIVE: To increase bioavailability of the water-based PFD eye drops, we prepared a viscous solution by adding hydroxypropyl methylcellulose (HPMC, F4M), which acted as a viscosity-enhancer. Subsequently, we compared the HPMC-based PFD solution with the water-based PFD eye drops.
MATERIALS AND METHODS: PFD solution with 1% HPMC (w/v) was prepared, and the viscosities at different shear rates were measured to investigate its rheology. PFD concentrations in the tear, aqueous humor, conjunctiva, cornea, and sclerae of New Zealand rabbits were detected at different time points with high-performance liquid chromatography (HPLC) following single instillation of the 0.5% PFD (w/v) water-based eye drops or HPMC-based solution.
RESULTS: Compared with the 0.5% water-based PFD eye drops, the HPMC-based solution increased the PFD levels in tears and prolonged the residence time from 10 to more than 20 min (p < .01). Consequently, the concentrations of PFD in aqueous humor, conjunctiva, cornea, and sclera were elevated to varying degrees until 90 min after topical administration.
CONCLUSIONS: The developed formulation possesses a same readily administration and simple preparation as the PFD eye drops; however, the HPMC-based solution exhibited the higher bioavailability.

Entities:  

Keywords:  Anti-scarring; HPMC-based solution; ocular drug delivery; pirfenidone; rheology

Mesh:

Substances:

Year:  2016        PMID: 27593737     DOI: 10.1080/03639045.2016.1230624

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  2 in total

1.  [Pirfenidone inhibits proliferation of rabbit tenon fibroblasts by down-regulating TGF-β3 in the TGF-β/Smad pathway].

Authors:  X Chen; Y Shen; H Zhao; W Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-11-20

2.  Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice.

Authors:  Carlos Daniel Diaz-Palomera; Isaac Alejandro Vidal-Paredes; Jose Navarro-Partida; Margarita Cid-Hernandez; Luis Carlos Rosales-Rivera; Ricardo De la Rosa-Bibiano; Hugo Christian Monroy-Ramirez; Arturo Santos; Juan Armendariz-Borunda
Journal:  Pharmaceutics       Date:  2022-01-28       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.